

Quick-Med
Technologies, Inc.



NIMBUS[®]

The Next Generation in Antimicrobial Protection

October, 2010

What is NIMBUS[®]?

NIMBUS represents a breakthrough in antimicrobial technology for wound care and other medical device applications

- ✓ No leaching
- ✓ No bacterial resistance
- ✓ No toxicity
- ✓ FDA-cleared as a *de novo* device

Next-generation NIMBUS technology provides cost-efficient, broad-spectrum, rapid-acting, patented antimicrobial protection



Non-leaching

- ✓ Permanently bonded to the dressing substrate
- ✓ Non-leaching
- ✓ Not depleted in use; remains at full strength. Never drops below the “minimum inhibitory concentration” level
- ✓ No migration from site to skin
- ✓ No need to discontinue use as wound begins to heal
- ✓ Designed for infection prevention in wounds

Other antimicrobials such as silver and PHMB leach from the dressing and deplete in order to work



No Bacterial Resistance

Bonded

- ✓ Active agent permanently bound to the dressing substrate
- ✓ No depletion of the biocide reservoir
- ✓ Active agent never falls below the minimum inhibitory concentration (MIC)

Large Molecule

- ✓ An extremely large molecule—molecular weight of 200,000 - 250,000 daltons.
- ✓ Too large to enter a microbe; bacteria cannot develop resistance to an agent that they cannot internalize
- ✓ Especially effective vs. resistant bacteria such as MRSA and VRE


No Resistance Developed

- ✓ Standard antimicrobial resistance assay
- ✓ *E.coli* (Gram-negative, very hardy cell wall construction, low susceptibility to quats) exposed to NIMBUS
- ✓ Survivors were isolated, cultured and re-exposed for ten successive experiments in which bacteria multiplied a million-fold in each experiment
- ✓ NIMBUS kill efficacy remained constant throughout ten iterations, demonstrating that bacteria had not increased resistance to NIMBUS



Non-toxic

- ✓ Active agent is permanently bonded to the wound dressing
- ✓ It does not leach away from the dressing
- ✓ Leaching antimicrobials can be toxic to good cells.
 - FDA approved “For Use Instructions” call for discontinuing their use after a specified period of time
- ✓ NIMBUS is the first and only non-leaching antimicrobial technology available for wound care



De Novo Technology

- ✓ FDA “de novo” clearance
- ✓ No predicate; nothing like it before
- ✓ Cleared as a device, not a drug or combination product
- ✓ Unique large molecule, permanently bound, non-leaching, non-depleting technology
- ✓ Unique FDA product code; own FDA guidance document
- ✓ Versatile
 - Absorbent dressings
 - Adhesives
 - Foams
 - Gauze
 - Hydrogels
 - Hydrocolloids
 - Polyurethane films
 - Incontinence products
 - Catheters

TIME

Microbe-Busting Bandages
Innovators Forging the Future




Wound Healing Society
Blue Ribbon Industrial R&D Awards
2006 , 2008, 2010




Mode of Action


Three-stage physical method of action



Attract



Bind



Disrupt & Destroy

An advanced cationic, high molecular weight antimicrobial polymer with high charge density

- Attracts bacterial cells and binds rapidly to displace calcium ions thus physically disrupting the cell wall
- The cell membrane collapses, and the cell dies as the cytoplasm leaks out
- High charge density ensures maximum efficacy will in the presence of body fluids

Broad Spectrum Microbicidal Efficacy*

	ATCC#	Percent Reduction
Staphylococcus aureus	12600	>99.9999%
Escherichia coli	15597	>99.9999%
Klebsiella pneumoniae	13833	>99.9999%
Pseudomonas aeruginosa	51447	>99.9999%
Proteus vulgaris	13115	>99.9999%
Serratia marcescens	13880	>99.9999%
Enterococcus faecalis	19433	>99.9999%
Enterobacter aerogenes	13048	>99.9999%
Listeria monocytogenes	13932	>99.9999%
MRSA	BAA-44	>99.9999%
VRE	700221	>99.9994%
<hr/>		
Bacteriophage MS-2 (<i>RNA virus</i>)		>99.994%
Bacteriophage PRD1 (<i>DNA virus</i>)		>99.87%

* Tested in 10% bovine serum (except viruses) after 18 hours of exposure

Rapid Kill Rate *Starts in Minutes**

NIMBUS starts immediately, even in high challenge environments* ...

Percentage Reduction Within Indicated Time

Time	<i>Staph. a.</i>	<i>E. Coli</i>	<i>Pseudo. A</i>
1 min	99.98780 %	96.99842%	99.98205%
10 min	99.99415%	99.99763%	99.98564%
20 min	99.99268%	99.99938%	99.99397%
30 min	99.99878%	99.99972%	99.99746%
60 min	99.9999%	99.99946%	99.99936%
4 hrs	99.9999%	99.99981%	99.99996%
8 hrs	99.9999%	99.99997%	99.99996%
12 hrs	99.9999%	99.99997%	99.99996%

* Tested in 10% bovine serum

... and is extremely long lasting due to its permanent bond



NIMBUS offers a superior performance, price and safety profile

Characteristic	NIMBUS	Silver	Triclosan	PHMB	Silane Quaternary
Effectiveness	High	High	Medium	Medium	Low
Persistence	High	Medium	Medium	Low	Low
Leaching	No	Yes	Yes	Yes	No
Resistance	No	Documented ¹	Documented ^{2,3}	Documented ^{4,5}	No
Economics	Low Cost	Expensive	Medium Cost	Medium Cost	Medium Cost

¹ Gupta, A., et al, *Nature Medicine* **5**:183-188. (1999)

² McMurray L.M., et al, *Nature* **398**: 531-532 (1998)

³ Heath, R. J., et al, *J. Biol. Chem.* **273**: 30316-30320 (1998)

⁴ Moore, L.E., et al, *Appl. Environ. Microbiol.* **74**: 4825-4834 (2008)

⁵ Allen, M.J., et al, *Microbiology* **152**: 989-1000 (2006)



NIMBUS[®] Summary

- ✓ Rapid acting, broad spectrum microbicide
- ✓ Highly effective against even drug-resistant bacteria
- ✓ Permanently bonded, non-leaching, no migration from site to skin, not depleted in use
- ✓ Large molecule (*2,000 antimicrobial units per molecule*)
- ✓ Not easily blocked by organics (*e.g., blood, urine, perspiration*)
- ✓ Highly cost effective relative to other microbicides
- ✓ Excellent human and environmental safety profile
- ✓ Does not induce drug resistance
- ✓ The only non-leaching antimicrobial FDA-cleared for wound healing



Quick-Med
Technologies, Inc.



***Developing Next Generation
Technologies***